Proposed New Score to Rate the Strength of Evidence and Its Application to Large-Scale Clinical Trials of Angiotensin-Receptor Blockers
スポンサーリンク
概要
- 論文の詳細を見る
Background Many large-scale clinical studies appear to be interpreted with bias and with hindsight. To select the best treatment, accurate evaluation of randomized controlled trials (RCTs) and fair comparison of the results using the concept of evidence-based medicine are critical. A scoring system has been developed to rate the scientific strength of evidence and thereby provide guidance for best clinical practice and for large-scale RCTs of angiotensin-receptor blockers (ARBs). Method and Results Positive evidence scores (ESs) were given based on whether specified study endpoints were proven and whether treatments tested made significant progress over current usual therapy. Retrospective ad hoc analyses data were not counted, in order to simplify the system and to avoid hindsight interpretations, even in cases that were medically significant. In fact, in more than half of the large-scale trials with ARBs examined, ad-hoc analyses had been retroactively performed. When such post-hoc analyses were not used, the ESs were positive with candesartan and valsartan for treatment of heart failure, irbesartan and losartan for nephropathy and losartan for hypertension. Applying the ES system, losartan was judged to be an ARB with the strongest evidence covering a wide range of clinical relevance. Conclusion ES is useful for quantifying and comparing the strength of evidence obtained in large-scale RCTs of ARBs. Several problems related to rating the evidence obtained from clinical trials were recognized in this study.
- 社団法人日本循環器学会の論文
- 2006-08-20
著者
-
Yamazaki Tsutomu
Department Of Applied Chemistry Tokyo University Of Agriculture And Technology
-
Yamazaki Tsutomu
Department Of Clinical Bioinformatics Graduate School Of Medicine University Of Tokyo
-
Yamazaki Tsutomu
Department Of Applied Chemistry Graduate School Of Engineering Tokyo University Of Agriculture And T
関連論文
- PE-536 The Relationships between BNP and AF in Japanese Patients(PE090,Heart Failure (Biomarker) 2 (M),Poster Session (English),The 73rd Annual Scientific Meeting of the Japanese Circulation Society)
- DPE-013 Determinants of Medication and Clinical Outcome in Japanese Atrial Fibrillation Patients under Rate Control Strategy : From Shinken Database 2004-6(DPE03,Atrial/Supraventricular Arrhythmia (Clinical/Treatment) (A),Digital Poster Session (English),
- OE-381 Role of Atrial Fibrillation in Congestive Heart Failure : A Prospective Cohort Study of Shinken Database 2004-6(OE64,Heart Failure (Diagnosis) (M),Oral Presentation (English),The 73rd Annual Scientific Meeting of The Japanese Circulation Society)
- OE-178 Comparison of Age-dependent Mortality between Patients with Cardiovascular Diseases and General Population in Japan(OE30,Preventive Medicine/Epidemiology/Education (H),Oral Presentation (English),The 73rd Annual Scientific Meeting of The Japanese C
- OE-079 Role of AF in BNP-based Risk Stratification : From an Analysis of Cardiovascular Morbidity in Japanese Patients(OE14,Heart Failure (Biomarker) (M),Oral Presentation (English),The 73rd Annual Scientific Meeting of The Japanese Circulation Society)
- OE-018 Occurrence of Warfarin Discontinuation and Its Determinants in Japanese AF Patients : From a Real-World Analysis(OE03,Thromboembolism/Antithrombotic Therapy/Thrombolysis (IHD),Oral Presentation (English),The 73rd Annual Scientific Meeting of The Ja
- OE-015 Effects of Warfarin on Mortality According to CHADS_2 Score and Components in Japanese AF Patients : From Shinken Database 2004-7(OE03,Thromboembolism/Antithrombotic Therapy/Thrombolysis (IHD),Oral Presentation (English),The 73rd Annual Scientific
- FRS-101 The Relationships between Estimated GFR and Prevalence of AF in Japanese Patients(FRS21,New Insights into Chronic Kidney Disease and Renal Circulation (H),Featured Research Session (English),The 73rd Annual Scientific Meeting of The Japanese Circu
- Japanese Randomized Trial for Investigation of a Combined Therapy of Amiodarone and Implantable Cardioverter Defibrillator in Patients With Ventricular Tachycardia and Fibrillation : The Nippon ICD Plus Pharmacologic Option Necessity (NIPPON) Study Design
- Body Size and Atrial Fibrillation in Japanese Outpatients